Zusammenfassung
Drogen kann man legal in der Apotheke kaufen oder illegal vom Dealer bekommen – die Wirkungen variieren stark. Alkohol in geringen Mengen ist eventuell sogar gut für die geistige Funktionsfähigkeit, zu viel kann jedoch tragisch enden. Von Marihuana, MDMA und Koks raten wir Ihnen dagegen ab. Außer Sie haben schon eine Demenz, dann ist der Zug sowieso schon abgefahren. Das Zeug von der Apotheke dagegen ist weitaus weniger wirksam, denn leider gibt es immer noch kein wundersames Heilmittel gegen die Demenz.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Change history
17 December 2020
In der zuerst veröffentlichten Fassung dieses Buches wurde der Name der Autorin Pia Linden uneinheitlich, teilweise mit zweitem Vornamen angegeben. Dies wurde nachträglich in den Kapiteln 4, 10, 12, 13, 15 und 16 verbessert.
Literatur
Akhondzadeh S, Noroozian M, Mohammadi M et al (2003) Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 28(1):53–59. https://doi.org/10.1046/j.1365-2710.2003.00463.x
Amen DG, Darmal B, Raji CA et al (2017) Discriminative properties of hippocampal hypoperfusion in marijuana users compared to healthy controls: implications for marijuana administration in Alzheimer’s dementia. J Alzheimers Dis 56(1):261–273. https://doi.org/10.3233/JAD-160833
Bachurin SO, Gavrilova SI, Samsonova A et al (2018) Mild cognitive impairment due to Alzheimer disease: contemporary approaches to diagnostics and pharmacological intervention. Pharmacol Res 129:216–226. https://doi.org/10.1016/j.phrs.2017.11.021
Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA („Ecstasy“) users. Neurology 51(6):1532–1537. https://doi.org/10.1212/wnl.51.6.1532
Boot BP, McGregor IS, Hall W (2000) MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 355(9217):1818–1821. https://doi.org/10.1016/S0140-6736(00)02276-5
Bryant PA, Trinder J, Curtis N (2004) Sick and tired: does sleep have a vital role in the immune system? Nat Rev Immunol 4(6):457–467. https://doi.org/10.1038/nri1369
Die Drogenbeauftrage der Bundesregierung (2020) Pressemitteilung vom 24. März 2020. Berlin
Eubanks LM, Rogers CJ, Beuscher AE et al (2006) A molecular link between the active component of marijuana and Alzheimer’s disease pathology. Mol Pharm 3(6):773–777. https://doi.org/10.1021/mp060066m
Fischer K, Melo van Lent D, Wolfsgruber S et al (2018) Prospective associations between single foods, Alzheimer’s dementia and memory decline in the elderly. Nutrients 10(7):852. https://doi.org/10.3390/nu10070852
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F et al (2000) Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatr 68(6):719–725. https://doi.org/10.1136/jnnp.68.6.719
Gupta S, Warner J (2008) Alcohol-related dementia: a 21st-century silent epidemic? Br J Psychiatr 193(5):351–353. https://doi.org/10.1192/bjp.bp.108.051425
Hamidpour M, Hamidpour R, Hamidpour S et al (2014) Chemistry, pharmacology, and medicinal property of sage (Salvia) to prevent and cure illnesses such as obesity, diabetes, depression, dementia, lupus, autism, heart disease, and cancer. J Irreprod Result 4(2):82–88. https://doi.org/10.4103/2225-4110.130373
Herning RI, Better W, Tate K et al (2005) Neuropsychiatric alterations in MDMA users: preliminary findings. Ann N Y Acad Sci 1053:20–27. https://doi.org/10.1196/annals.1344.003
Ilhan A, Gurel A, Armutcu F et al (2004) Ginkgo biloba prevents mobile phone-induced oxidative stress in rat brain. Clin Chim Acta 340(1–2):153–162. https://doi.org/10.1016/j.cccn.2003.10.012
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2007) Cholinesterasehemmer bei Alzheimer Demenz. Abschlussbericht. https://www.iqwig.de/de/projekte-ergebnisse/projekte/arzneimittelbewertung/2010-oder-frueher/a05-19a-cholinesterasehemmer-bei-alzheimer-demenz.1141.html Zugegriffen: 21. Mai 2020
Jovanovski D, Erb S, Zakzanis KK (2005) Neurocognitive deficits in cocaine users: a quantitative review of the evidence. J Clin Exp Neuropsychol 27(2):189–204. https://doi.org/10.1080/13803390490515694
Johnson JW, Kotermanski SE (2006) Mechanism of action of memantine. Curr Opin Pharmacol 6(1):61–67. https://doi.org/10.1016/j.coph.2005.09.007
Kalechstein AD, De La Garza R, Mahoney JJ et al (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 189(4):531–537. https://doi.org/10.1007/s00213-006-0601-2
Krishnan S, Cairns R, Howard R (2009) Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009(2): CD007204. https://doi.org/10.1002/14651858.CD007204.pub2
Matsunaga S, Kishi T, Iwata N (2015) Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS ONE 10(4):e0123289. https://doi.org/10.1371/journal.pone.0123289
Maust DT, Bonar EE, Ilgen MA et al (2016) Agitation in Alzheimer disease as a qualifying condition for medical marijuana in the United States. Am J Geriatr Psychiatry 24(11):1000–1003. https://doi.org/10.1016/j.jagp.2016.03.006
OECD (2019) Health at a glance 2019: OECD indicators. OECD Publishing, Paris
Peacock A, Leung J, Larney S et al (2018) Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 113(10):1905–1926. https://doi.org/10.1111/add.14234
Perry E, Howes MJR (2011) Medicinal plants and dementia therapy: herbal hopes for brain aging? CNS NeurosciTher 17(6):683–698. https://doi.org/10.1111/j.1755-5949.2010.00202.x
Peters R, Peters J, Warner J et al (2008) Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37(5):505–512. https://doi.org/10.1093/ageing/afn095
Phu HT, Thuan DTB, Nguyen THD et al (2020) Herbal medicine for slowing aging and aging-associated conditions: efficacy, mechanisms, and safety. Curr Vasc Pharmacol. https://doi.org/10.2174/1570161117666190715121939
Pinder RM, Sandler M (2004) Alcohol, wine and mental health: focus on dementia and stroke. J Psychopharmacol 18(4):449–456. https://doi.org/10.1177/0269881104047272
Schierenbeck T, Riemann D, Berger M et al (2008) Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Med Rev 12(5):381–389. https://doi.org/10.1016/j.smrv.2007.12.004
Schwarzinger M, Pollock BG, Hasan OS et al (2018) Contribution of alcohol use disorders to the burden of dementia in France 2008–2013: a nationwide retrospective cohort study. Lancet Public Health 3(3):e124–e132. https://doi.org/10.1016/S2468-2667(18)30022-7
Ströhle A, Schmidt DK, Schultz F et al (2015) Drug and exercise treatment of Alzheimer disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. Am J Geriatr Psychiatr 23(12):1234–1249. https://doi.org/10.1016/j.jagp.2015.07.007
Sun Y, Lai MS, Lu CJ et al (2008) How long can patients with mild or moderate Alzheimer’s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population-based study. Eur J Neurol 15(3):278–283. https://doi.org/10.1111/j.1468-1331.2007.02049.x
van Amsterdam J, Nutt D, Phillips L et al (2015) European rating of drug harms. J Psychopharmacol 29(6):655–660. https://doi.org/10.1177/0269881115581980
Weier M, Hall W (2017) The use of cannabinoids in treating dementia. Curr Neurol Neurosci Rep 17(8):56. https://doi.org/10.1007/s11910-017-0766-6
Weinmann S, Roll S, Schwarzbach C et al (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10:14. https://doi.org/10.1186/1471-2318-10-14
World Health Organization (WHO) (2019) Risk reduction of cognitive decline and dementia: WHO guidelines. Risk reduction of cognitive decline and dementia: WHO guidelines. https://www.who.int/mental_health/neurology/dementia/guidelines_risk_reduction/en/. Zugegriffen: 25. Mai 2020
Yuan Q, Wang CW, Shi J et al (2017) Effects of Ginkgo biloba on dementia: an overview of systematic reviews. J Ethnopharmacol 195:1–9. https://doi.org/10.1016/j.jep.2016.12.005
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2020 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Linden, P. (2020). Pharmakologische Akzeleration der Demenzentwicklung: Von Alkohol, Drogen und Medikamenten. In: Der andere Anti-Demenz-Ratgeber. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60606-3_13
Download citation
DOI: https://doi.org/10.1007/978-3-662-60606-3_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-60605-6
Online ISBN: 978-3-662-60606-3
eBook Packages: Medicine (German Language)